8 March 2024 in Drug Discovery Today
Design-Make-Test-Analyse (DMTA) is the discovery cycle through which molecules are designed, synthesised, and assayed to produce data that in turn are analysed to inform the next iteration. The process is repeated until viable drug candidates are identified, often requiring many cycles before reaching a sweet spot. The advent of artificial intelligence (AI) and cloud computing presents an opportunity to innovate drug discovery to reduce the number of cycles needed to yield a candidate. Here, we present the Predictive Insight Platform (PIP), a cloud-native modelling platform developed at AstraZeneca. The impact of PIP in each step of DMTA, as well as its architecture, integration, and usage, are discussed and used to provide insights into the future of drug discovery. Teaser: This review of the role, impact, and architecture of AstraZeneca's Predictive Insight Platform (PIP), a cloud-native modelling platform that aims to accelerate drug discovery, offers perspective on the evolution of R&D in pharma.
13 March 2023 in Scientific Reports
Hydrogen bonding is an interaction of great importance in drug discovery and development as it may significantly affect chemical and biological processes including the interaction of small molecules with other molecules, proteins, and membranes. In particular, hydrogen bonding can impact drug-like properties such as target affinity and oral availability which are critical to developing effective pharmaceuticals, and therefore, numerous methods for the calculation of properties such as hydrogen-bond strengths, free energy of hydration, or water solubility have been proposed over time. However, the accessibility to efficient methods for the predictions of such properties is still limited. Here, we present the development of Jazzy, an open-source tool for the prediction of hydrogen-bond strengths and free energies of hydration of small molecules. Jazzy also allows the visualisation of hydrogen-bond strengths with atomistic resolution to support the design of compounds with desired properties and the interpretation of existing data. The tool is described in its implementation, parameter fitting, and validation against two data sets of experimental hydration free energies. Jazzy is also applied against two chemical series of bioactive compounds to show that hydrogen-bond strengths can be used to understand their structure–activity relationships. Results from the validations highlight the strengths and limitations of Jazzy, and suggest its suitability for interactive design, screening, and machine-learning featurisation.
17 September 2019 in Journal of Chemical Information and Modeling
Reaction classification has often been considered an important task for many different applications, and has traditionally been accomplished using hand-coded rule-based approaches. However, the availability of large collections of reactions enables data-driven approaches to be developed. We present the development and validation of a 336-class machine learning-based classification model integrated within a Conformal Prediction (CP) framework in order to associate reaction class predictions with confidence estimations. We also propose a data-driven approach for 'dynamic' reaction fingerprinting to maximise the effectiveness of reaction encoding, as well as developing a novel reaction classification system that organises labels in four hierarchical levels (SHREC: Sheffield Hierarchical REaction Classification). We show that the performance of the CP augmented model can be improved by defining confidence thresholds to detect predictions that are less likely to be false. For example, the external validation of the model reports 95% of predictions as correct by filtering out less than 15% of the uncertain classifications. The application of the model is demonstrated by classifying two reaction datasets: one extracted from an industrial ELN and the other from the medicinal chemistry literature. We show how confidence estimations and class compositions across different levels of information can be used to gain immediate insights on the nature of reaction collections and hidden relationship between reaction classes.
27 December 2022 in Journal of Chemical Information and Modeling
16 January 2026 in Drug Discovery Today
LSLakshidaa Saigiridharan
+4
Agentic systems that are based on large language models (LLMs) have emerged as promising tools in the chemistry domain over the past few years. Early examples included work on CoScientist, Chemcrow, and LLM-RDF, which showcased the potential of agentic systems to assist in chemical research, in the orchestration of cheminformatics tools, and in synthetic reaction development. Despite this, the current literature lacks examples of the real-world adoption of such systems in drug discovery. We present such an example by describing our work on an agentic system called ChatInvent, which has been integrated into the discovery pipeline at AstraZeneca to aid in molecular design and synthesis planning. We discuss how the system evolved from a proof-of-concept single agent into an extensible, robust, and scalable multi-agent architecture with a graphical user interface. We emphasize the lessons learnt and the challenges that persist as we continue to work on this project, and share our perspectives on the future of agentic systems in our domain.
7 August 2026 in Nature Reviews Drug Discovery
Artificial intelligence (AI) in drug discovery has attracted increasing interest over the past decade. It is now time for a critical review of progress in the field: where did we advance — and where are we yet to see impact — when it comes to what matters in drug discovery, which is to deliver safer and more efficacious medicines to patients faster? Although a wide variety of AI methods have been developed, applied and benchmarked, evidence of their clinically relevant impact is, so far, disappointingly limited. In this Perspective we discuss potential reasons, including an insufficient focus on clinical translation during model development, difficulties with applying AI algorithms on conditional life science data, and insufficient problem definitions and the resulting underspecification of computational models for real-world use cases. ‘Technology push’ compared with ‘science pull’ is also likely to be an underlying factor, as well as the substantial time required to operationalize technical capabilities into systems that are sufficiently scaled and accessible for users. We provide recommendations for the development of AI in drug discovery with the aim of increasing its translational relevance. For example, benchmarking studies of AI tools in drug discovery need to move on from model validation and instead focus on their ability to improve decision making.